Home › Funds › Logos Global Management LP › BNTX
Logos Global Management LP position in BNTX
BIONTECH SE · Health Care
Logos Global Management LP reported holding 650,000 shares of BNTX (BIONTECH SE) in its Q3 2026 13F filing — a position valued at US$63.9M, representing 3.84% of its reported portfolio and ranking #7 among its reported holdings. Logos Global Management LP has disclosed BNTX holdings in 4 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Logos Global Management LP's BNTX position evolved
Logos Global Management LP first disclosed a stake in BNTX in Q4 2024 at 300,000 shares (US$34.2M). The position peaked in Q2 2026 at 1,015,000 shares, worth US$94.4M. Across 4 filings, Logos Global Management LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 650,000 shares valued at US$63.9M — a reduction of -365,000 shares quarter over quarter.. Notable position changes include a 33% trim in Q1 2025 (shares rose 17% over the following quarter), a 36% trim in Q3 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 300.00K | $34.19M | New |
| Q1 2025 | 200.00K | $18.21M | Reduce |
| Q2 2026 | 1.01M | $94.45M | New |
| Q3 2026 | 650.00K | $63.90M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BNTX and 13F data
BNTX (BIONTECH SE) is a Health Care company. 27 other funds we track also report a position in BNTX — the largest reported positions include Davern Capital Partners, LP (US$67.1M), GSK plc (US$65.7M), Long Focus Capital Management, LLC (US$62.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BNTX
- Davern Capital Partners, LP 682.15K sh · $67.06M · Q3 2026
- GSK plc 668.53K sh · $65.72M · Q3 2026
- Long Focus Capital Management, LLC 632.00K sh · $62.13M · Q3 2026
- SAMLYN CAPITAL, LLC 561.70K sh · $55.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 470.00K sh · $43.73M · Q2 2026
More on Logos Global Management LP
FAQ
How long has Logos Global Management LP held BNTX?
Logos Global Management LP has disclosed BNTX holdings in 4 of the last 8 reported quarters, going back to Q4 2024.
What is Logos Global Management LP's current position in BNTX?
As of Q3 2026, Logos Global Management LP holds 650.00K shares of BNTX (BIONTECH SE), valued at $63.90M, representing 3.84% of its reported portfolio and ranking #7.
Has Logos Global Management LP been buying or selling BNTX?
In the latest 13F filing (Q3 2026), Logos Global Management LP reduced its position in BNTX. The position peaked in Q2 2026 at 1.01M shares.
Which other funds hold BNTX?
Other major institutional holders of BNTX include Davern Capital Partners, LP, GSK plc, Long Focus Capital Management, LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.